Management of patients with signs and symptoms of primary and secondary gout (recurrent acute attacks, arthropathy, tophi, radiographic changes of gout or associated uric acid nephrolithiasis). Management of patients with leukemia, lymphoma and solid tumor malignancies who are undergoing chemotherapy expected to result tumor lysis and subsequent elevations of serum and urinary uric acid concentrations. Allopurinol therapy should be discontinued when the potential for hyperuricemia is no longer present. For the management of patients with recurrent calcium oxalate renal calculi in males whose urinary urate excretion >800mg daily and in females whose urinary urate excretion exceeds 750mg daily. The use of allopurinol for this condition must be carefully evaluated initially and reevaluated periodically to determine that therapy with the drug is beneficial and outweighs the risks.

This is not a substitute for consulting your doctor. Seek professional advice if you are experiencing any illness or symptoms.

Adult: 100mg/day for 2 week after the pain & swelling of acute gouty arthritis have subsided. Titrate dose by 50-100mg/day every 2-4 week to achieve serum uric acid <6 mg/dL (0.36 mmoI/L) Max: 300mg/day. Management of leukemia, lymphoma & solid tumor malignancies Adult 600-800MG/day for 2-3 days. Management of recurrent Ca oxalate renal calculi Initially 200-300mg/day as single or in divided doses.

Should be taken with food.